复发性非小细胞肺癌的挽救性胸部再放疗:临床疗效与巩固免疫治疗的影响
该研究纳入2011至2021年间130例因非小细胞肺癌孤立性局部区域复发接受挽救性胸部再放疗(剂量60-72 Gy)的患者。全组中位总生存(OS)17.4个月,3年OS率25.9%;再放疗后接受巩固免疫治疗者的OS和无局部区域生存均优于未接受者。9例(6.9%)发生5级毒性。
要点
- 全组中位OS 17.4个月(95%CI 14.1-22.9),中位PFS 8.1个月(95%CI 6.7-10.8)。
- 接受巩固免疫治疗者中位OS 27.8个月 vs 未接受者15.8个月(p=0.035)。
- 9例(6.9%)发生5级毒性,再放疗后90天内住院与OS相关(HR 2.03)。
核心结论
- 胸部再放疗是选择性患者中与长期治愈相关的安全治疗选择,巩固免疫治疗与改善的临床结局相关。
研究设计与样本
- 2011至2021年间1219例非小细胞肺癌患者接受胸部放疗,其中130例接受再放疗,剂量60-72 Gy。
主要发现
- 全组中位OS为17.4个月(95%CI 14.1-22.9),中位PFS为8.1个月(95%CI 6.7-10.8)。
- 3年OS率为25.9%(95%CI 19.3-34.8%),3年累积远处失败率为44%,局部区域失败率为46%。
- 再放疗后接受巩固免疫治疗者中位OS为27.8个月(95%CI 18.4-未达到)vs 未接受者15.8个月(95%CI 12.1-22.1),p=0.035。
- 再放疗后接受巩固免疫治疗者中位无局部区域生存为22.8个月(95%CI 9.8-未达到)vs 未接受者8.8个月(95%CI 7.6-12.6),p=0.009。
- 多因素分析显示巩固免疫治疗(HR 0.56,95%CI 0.32-1.03,p=0.065)和再放疗后90天内住院(HR 2.03,95%CI 1.24-3.33,p=0.005)与OS相关。
关键数值与推荐
- 再放疗剂量范围为60-72 Gy。
- 毒性结局包括3级及以上非血液学事件、再放疗后90天内住院和5级毒性(CTCAE v5.0);9例(6.9%)发生5级毒性。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe clinical outcomes in a large patient cohort treated with salvage thoracic reirradiation (reRT) for isolated locoregional recurrence of non-small cell lung cancer (NSCLC). METHODS: Between 2011 and 2021, 1219 patients received thoracic radiotherapy for NSCLC; 130 patients underwent reRT, with doses ranging from 60-72 Gy. Primary outcomes were overall survival (OS), progression-free survival (PFS), and reRT toxicity; secondary outcomes were locoregional failure (LRF) and distant failure (DF). The Kaplan-Meier method and cumulative incidence with death as a competing risk were used for analysis, with multivariable modeling via Cox proportional hazards. Toxicity outcomes included grade 3 + non-hematologic event, hospitalization within 90 days of reRT, and grade 5 toxicity per Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: Median OS and PFS for the entire cohort were 17.4 months (95 % CI 14.1-22.9) and 8.1 months (95 % CI 6.7-10.8), respectively. 3-year OS was 25.9 % (95 % CI 19.3-34.8 %). The 3-year cumulative incidence of DF and LRF were 44 % and 46 %, respectively. Recipients of consolidative immunotherapy after reRT had improved OS (27.8 months [95 %CI 18.4-not reached] vs 15.8 months [95 %CI 12.1-22.1]; p = 0.035) and locoregional-free survival (22.8 months [95 %CI 9.8-not reached] vs 8.8 months [95 %CI 7.6-12.6]; p = 0.009). Multivariable analysis showed consolidative immunotherapy (HR 0.56, 95 %CI 0.32-1.03, p = 0.065) and hospitalization within 90 days of reRT (HR 2.03, 95 %CI 1.24-3.33, p = 0.005) were associated with OS. Nine patients (6.9 %) experienced grade 5 toxicities. CONCLUSION: Thoracic reRT is a safe treatment option associated with long-term cure in select patients. Immunotherapy consolidation was associated with improved clinical outcomes.
引用
- Rocchetti J, Yegya-Raman N, Iocolano M, et al. Salvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy. Radiother Oncol. 2025. PMID: 40300728. doi:10.1016/j.radonc.2025.110911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。